HDII — Hypertension Diagnostics Income Statement

0.000.00%

Last trade - 00:00

FinancialsHighly SpeculativeMicro Cap

Annual income statement for Hypertension Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2011 June 30th	2012 June 30th	2016 December 31st	2017 December 31st	2018 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	—	—	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	3.16	3.57	3.68	3.79
Cost of Revenue
Gross Profit	0	-0.112	0.551	0.752	0.954
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	0.366	4.52	4.22	4.08	3.95
Operating Profit	-0.366	-1.36	-0.656	-0.404	-0.161
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.355	-1.47	-0.622	-0.369	-0.125
Provision for Income Taxes
Net Income After Taxes	-0.355	-1.47	-0.622	-0.369	-0.125
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	0.406	-1.26	-0.622	-0.369	-0.125
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	0.406	-1.26	-0.622	-0.369	-0.125
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.008	-0.031	-0.012	-0.007	-0.002
Dividends per Share